Skip to main content
C

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,504 across all filing types
Latest filing 2025-06-02 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2025
Regulatory Filings Classification · 1% confidence The document is a regulatory monthly return (Form FF301) filed with the Hong Kong Exchange detailing movements in issued shares, treasury shares, share options, and repurchases for the month ended 31 May 2025. It is not an earnings release, annual report, or proxy statement, nor an announcement of dividend or capital raising. It falls under general regulatory filings required by the exchange, with no more specific category among the given options.
2025-06-02 English
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 30 MAY 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement of the poll results from the Annual General Meeting held on 30 May 2025. It lists resolutions voted on and the number of votes for and against each resolution. This corresponds exactly to a Declaration of Voting Results & Voting Rights Announcements. Therefore, the filing type is DVA.
2025-05-30 English
VOLUNTARY ANNOUNCEMENT - POTENTIAL LICENSE AND COLLABORATION
Regulatory Filings Classification · 1% confidence The document is a short voluntary announcement by CSPC Pharmaceutical concerning potential licensing and collaboration transactions. It does not present financial results (ER/IR), board changes (MANG), dividend notice (DIV), share issues (SHA), insider dealings (DIRS), M&A or takeover proposals (TAR), nor detail environmental/social disclosures (SR). It is also not pointing to or publishing a full report (RPA) but rather is a standalone announcement of an anticipated commercial transaction. Therefore, it does not match any specific specialized category and should be classified under the fallback Regulatory Filings category (RNS).
2025-05-30 English
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2025
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Results' announcement for CSPC Pharmaceutical Group Limited for the three months ended 31 March 2025. It contains detailed financial highlights, revenue breakdowns, profit analysis, and business review sections. While it is an announcement, it provides substantive financial data and analysis for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-29 English
VOLUNTARY ANNOUNCEMENT - CPO301 GRANTED THE THIRD FAST TRACK DESIGNATION BY U.S. FDA FOR THE TREATMENT OF ADULT PATIENTS WITH NSCLC
Regulatory Filings Classification · 1% confidence The document is a corporate announcement filed on the Hong Kong Exchange (“voluntary announcement”) about an FDA Fast Track designation for a drug under development, not an earnings release, management change, or any of the highly specific categories (e.g., financial report, director dealing, M&A, dividends, etc.). It does not provide financial results, board changes, or a formal report; it’s a general regulatory/corporate update. Therefore, the best fit is the fallback category “Regulatory Filings (RNS).”
2025-05-19 English
VOLUNTARY ANNOUNCEMENT - JMT106 (BISPECIFIC FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 1% confidence The document is a short voluntary corporate announcement notifying investors of clinical trial approval for a drug. It contains no financial results, no report attachments, and does not fit any specific category like earnings, M&A, or board changes. It is a general regulatory-type announcement, so it falls under the fallback ‘Regulatory Filings’ category (RNS).
2025-05-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.